Oxyglobin: veterinary evidence and history
Oxyglobin, hemoglobin glutamer-200 (bovine), is a historical veterinary hemoglobin-based oxygen carrier. This guide connects its controlled canine record, clinical publications and descriptive case archive.
A product-specific veterinary precedent
The veterinary regulatory material records the 1998 FDA approval of Oxyglobin for anemia in dogs under NADA 141-067. This is a historical product- and species-specific precedent. It does not establish current supply or approval of the BHOC platform.
Oxyglobin, Hemopure/HBOC-201 and BHOC should remain distinguishable in a publication or research proposal. Their names, formulations, study populations and regulatory histories cannot be substituted for one another.
Canine anemia: controlled evidence and clinical context
The FDA evidence page distinguishes its controlled 24-hour support endpoint from survival. That distinction matters when interpreting an oxygen-carrying intervention alongside treatment of the underlying condition.
The catalogue also includes a prospective randomized comparison of Oxyglobin and packed red cells in 12 dogs with babesiosis, and a separate canine hypovolemia study of intestinal perfusion and oxygenation. Their disease and model settings should be retained. They are not universal demonstrations for every cause of canine anemia.
Read the canine case archive as descriptive evidence
Biopure’s historical Case Listing Book II distinguishes 885 manufacturer-received canine reports from 146 selected printed case vignettes. The archive is useful for understanding clinical settings, treatment sequences and the questions practitioners were asking.
Selection, incomplete fields and concurrent treatments limit interpretation. The printed cases should not be converted into a treatment efficacy or survival rate. The critical archive review keeps these limitations separate from the controlled FDA evidence.
Cats and horses require their own evidence
The feline page links retrospective Oxyglobin experience, including a 48-cat report and a 72-cat series cited by EveryCat. These are historical reports in cats, not a feline approval statement or new BHOC outcomes.
The equine literature includes a pharmacokinetic study of hemoglobin glutamer-200 bovine. A pharmacokinetic report does not establish clinical benefit, an equine indication or an appropriate dose for another formulation.
Connect the blood measurement to oxygen function
The existing veterinary science page explains the distinction between packed cell volume and cell-free plasma hemoglobin. Oxygen content, circulation, affinity, unloading and tissue demand need to be interpreted together.
BHOC, Biological Hemoglobin Oxygen Carrier, is being developed within Precision Oxygen Therapeutics. Historical Oxyglobin findings can inform study design, while BHOC-specific characterization, species-specific safety and functional outcomes require separate evidence.